A5017769557- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- RNA modifications and cancer
- Neutropenia and Cancer Infections
- Myasthenia Gravis and Thymoma
- Colorectal Cancer Treatments and Studies
- Gestational Trophoblastic Disease Studies
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Occupational and environmental lung diseases
- Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Pituitary Gland Disorders and Treatments
- Acute Lymphoblastic Leukemia research
- Cancer-related molecular mechanisms research
- Ferroptosis and cancer prognosis
- Multiple and Secondary Primary Cancers
- Chronic Myeloid Leukemia Treatments
Instituto Nacional de Enfermedades Neoplásicas
2016-2025
Universidad Peruana Cayetano Heredia
2020-2025
EsSALUD
2014-2024
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Cancer Institute (WIA)
2019
Université de Reims Champagne-Ardenne
2012
Chulalongkorn University
2009-2010
GlaxoSmithKline (United States)
2010
GlaxoSmithKline (France)
2009
Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived c-Kit or epidermal receptor (EGFR) human 2 (HER2/neu), respectively. In cervical cancer, EGFR HER2/neu overexpression high microvascular density correlate with survival.Patients measurable stage IVB persistent/recurrent carcinoma not amenable to curative therapy at least one prior regimen in the metastatic setting were randomly assigned a ratio of 1:1:1 pazopanib...
BackgroundThere are well-known differences in gender outcome non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the influence of patients with NSCLC treated targeted therapy immunotherapy.MethodsWe performed a series meta-analysis compare routine setting for overall survival progression-free (PFS) phase III comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, 6, EURTAC, ENSURE WTJOG); ALK (ASCEND 4,...
Standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy repeated at 3-week intervals is difficult to deliver in elderly patients with non-Hodgkin's lymphoma (NHL). The use of hemopoietic growth factors may decrease the hematologic toxicity allow delivery full-dose CHOP.We conducted a phase II trial addition granulocyte-macrophage colony-stimulating factor (GM-CSF) CHOP NHL older than 60 years age. Twenty-six previously untreated were assessable; median age was...
Abstract DDIT4 gene encodes a protein whose main action is to inhibit mTOR under stress conditions whilst several in vitro studies indicate that its expression favors cancer progression. We have previously described an independent prognostic factor for tripe negative breast resistant neoadjuvant chemotherapy. herein report high related the outcome (recurrence-free survival, time progression and overall survival) types. performed silico analysis online platforms, pooled datasets from KM...
Mutations in STK11 (STK11Mut) and, frequently co-occurring, KEAP1 mutations (KEAP1Mut) are associated with poor survival metastatic Non-small Cell Lung Cancer (mNSCLC) patients treated immunotherapy. However, there limited data regarding the prognostic or predictive significance of these genomic alterations among Hispanics.This retrospective study analyzed a cohort Hispanic (N = 103) diagnosed mNSCLC from US and seven Latin American countries (LATAM) immune checkpoint inhibitors (ICI) alone...
Background To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ beyond line, versus matched receiving standard chemotherapy special characterization hyperprogressors. Methods A retrospective cohort study 296 unresectable/metastatic NSCLC treated either, second‐, third‐ fourth‐line was conducted. comparison a historical first‐line and random forest tree analysis to characterize hyperprogressors...
Despite osimertinib being the standard therapy for advanced EGFR T790M mutation positive NSCLC, in many Latin American countries, access to molecular testing and targeted therapies is limited, directly impacting patient outcomes. This study describes real-world management outcomes of Peruvian patients with EGFR-mutated NSCLC who develop mutation. We conducted a multicenter retrospective including from nine institutions, both public private, progressed first-line TKI developed mutation,...
There are different biological and clinical patterns of lung cancer between genders indicating intrinsic differences leading to increased sensitivity cigarette smoke-induced DNA damage, mutational KRAS better outcomes in women while at gene-expression levels was not previously reported. Here we show an enrichment immune genes NSCLC compared men. We found a GSEA analysis (by processes annotated from Gene Ontology) six public datasets repeated observation gene sets women. "Immune system...
<b><i>Objective:</i></b> Latin American countries are heterogeneous in terms of lung cancer incidence and exposure to potential carcinogens. We evaluated the frequency clinical characteristics <i>ALK</i> rearrangements (<i>ALKr</i>) America. <b><i>Methods:</i></b> A total 5,130 patients from 10 were screened for inclusion. <i>ALKr</i> detection was performed by fluorescence situ hybridization (FISH),...
Lung cancer is still a prevalent and fatal neoplasm in developing countries. In the last decades, chemotherapy (CHT) maintenance occupied an important role treatment, as well targeted therapies. We aimed to evaluate survival impact of therapy advanced lung at private Peruvian institution (Oncosalud - AUNA).We reviewed retrospectively medical records patients with advanced-stage non-small cell (NSCLS) (clinical stage III-IV) who received CHT treatment target (TT) or CHT. The was assessed by...
Aim: To correlate levels of tumor-infiltrating lymphocytes (TIL) evaluated using the International Immuno-Oncology Biomarker Working Group methodology, and both density immune cell clinicopathological features in different malignancies. Methods: 209 pathological samples from gastric cancer, cervical cancer (CC), non-small-lung cutaneous melanoma (CM) glioblastoma were tested for TIL hematoxylin eosin, CD3+, CD4+, CD8+, CD20+, CD68+ CD163+ cells by digital analysis. Results: higher invasive...
The KRAS exon 2 p. G12C mutation in patients with lung adenocarcinoma has been increasing relevance due to the development and effectiveness of new treatment medications. Studies around different populations indicate that regional variability between ethnic groups ancestries could play an essential role developing this molecular alteration within cancer.In a prospective retrospective cohort study on samples from 1000 administrative regions Colombia were tested for p.G12C mutation. An...
Little data are available concerning the role of general practitioners (GPs) in diagnosis melanoma.To evaluate actual GPs a population-based study covering five regions France and 8·2 million inhabitants.A survey cancer registries pathology laboratories, questionnaires to were used identify incident melanomas 2008, characteristics patients (age, sex, area residence, social isolation), tumours (Breslow, ulceration, location, histological type), (training, conditions practice), their influence...
Introduction Breast cancer is a heterogeneous disease, and the distribution of different subtypes varies by race/ethnic category in United States country. Established breast cancer-associated factors impact subtype-specific risk; however, these included limited or no representation Latin American diversity. To address this gap knowledge, we report description demographic, reproductive, lifestyle age at diagnosis disease subtype for The Peruvian Genetics Genomics Cancer (PEGEN-BC) study....